Opus Genetics (IRD) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Opus Genetics (IRD) has outperformed Relmada Therapeutics (RLMD) over the past year, gaining 117.2% versus a gain of 63.3%. Over five years, IRD leads with a +2.8% price change compared with -86.2% for RLMD. Opus Genetics is the larger company by market cap ($366.9 million vs $346.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRD | RLMD |
|---|---|---|
| Share price | $4.41 | $3.25 |
| Market cap | $366.89M | $346.68M |
| 1-day change | +0.68% | -0.91% |
| YTD return | +119.40% | -32.71% |
| 1-year return | +117.24% | +63.32% |
| 5-year return | +2.80% | -86.25% |
| EPS (TTM) | $-1.27 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.07 | $8.00 |
| 52-week low | $1.70 | $1.80 |
| Distance from 52-week high | -37.62% | -59.38% |
| Average volume | 2.35M | 1.34M |
| Shares outstanding | 83.20M | 106.67M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRD has outperformed RLMD by 53.9 percentage points over the past year.
IRD vs RLMD FAQ
Which is bigger, Opus Genetics or Relmada Therapeutics?
Opus Genetics (IRD) is larger, with a market capitalization of $366.89M compared with $346.68M for Relmada Therapeutics (RLMD).
Which stock has performed better over the past year, IRD or RLMD?
IRD returned +117.24% over the past 12 months, compared with +63.32% for RLMD (price return, excluding dividends). Past performance does not predict future results.
Are Opus Genetics and Relmada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.